## RGNX: REGENXBIO Inc. - XLV: Healthcare

### Executive Summary

PARABOLIC warning: MRS_20 at 10.6% exceeds exhaustion threshold (10.0%). Extreme momentum typically precedes mean reversion. Consider profit-taking or tight stops.

- **Horizon:** 1-5 days (momentum)
- **Risk Profile:** High - extreme momentum reversal risk
- **Stop Type:** Fixed 2xATR ($12.69)
- **If Wrong:** Exit on momentum reversal or stop hit
- **Invalidation:** MRS_20 drops below exhaustion threshold

### News

- **Articles:** 3
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. REGENXBIO to Present at the 44th Annual J.P. Morgan Healthcare Conference**
- Source: The AI Journal | 20251218T120959 | Neutral | Relevance: 100%
- REGENXBIO Inc. (Nasdaq: RGNX) announced it will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 10:30 a.m. PT in San Francisco. The presentation will be webcast live and an archived replay will be available on the company's website. REGENXBIO is a biotechnology company focused on advancing AAV gene therapies for rare and retinal diseases.

**2. Stifel raises Regenxbio stock price target to $45 on upcoming catalysts**
- Source: Investing.com Nigeria | 20251219T150915 | Bullish | Relevance: 100%
- Stifel has increased its price target for Regenxbio Inc. (NASDAQ:RGNX) to $45.00 from $40.00, maintaining a Buy rating based on upcoming catalysts in 2026. The gene therapy company is approaching potential commercial status for its lead candidate RGX-121 and other programs for Duchenne muscular dystrophy and wet age-related macular degeneration. Despite not currently being profitable, Regenxbio's financial position is stable with potential non-dilutive funding, and analysts anticipate significant sales growth.

**3. Stifel Raises Price Target for Regenxbio (RGNX) to $45 | RGNX St**
- Source: GuruFocus | 20251219T150915 | Bullish | Relevance: 100%
- Stifel has maintained its 'Buy' rating on Regenxbio (RGNX) and increased the price target from $40.00 to $45.00, indicating a 12.5% potential upside. This decision aligns with a consistent positive outlook from several other analysts. Analyst consensus points to an "Outperform" status with an average target price of $32.15, suggesting a 126.12% upside from the current price.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-19 | Stifel | $45 | $40 | +12% |
| 2025-12-15 | Leerink Partner | $20 | $16 | +25% |
| 2025-11-20 | Chardan Capital | $52 | $52 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-19 | Stifel | main | Buy |
| 2025-12-15 | Leerink Partner | main | Outperform |
| 2025-11-20 | Chardan Capital | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 2 ($0.34M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 62.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- JPMORGAN CHASE & CO: 16.0% (+109.6%)
- Blackrock Inc.: 12.6% (-5.7%)
- Redmile Group, LLC: 9.3% (-1.7%)
- Vanguard Group Inc: 6.6% (-2.4%)
- State Street Corpora: 3.9% (+7.7%)

### Key Risks

1. Elevated short interest (13.0%): bears positioning against stock.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.26 indicates undervaluation relative to growth. Balance sheet: strong liquidity (2.7x). Revenue growth strong at 39% YoY. Analyst sentiment positive (2 raises, avg +19%). Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $0.7B |
| Beta | 1.14 |
| 52W Range | $5.04 - $15.20 |
| Short Interest | 13.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.26 |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_20 stable at 10.6% (minimal 5-day change). Extended beyond STRENGTH zone (10.6% > 10.0%), caution on chasing. MRS_5 at 4.2% confirms short-term momentum alignment. AM_20 at 11.0% shows strong absolute momentum above own 20MA. Outperforming sector by 10.7pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: +SUH (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 10.64% (CS: 97) | Strong |
| RSI_14 | 64.1 | Neutral |
| MACD Histogram | 0.08 | Bullish |
| vs SMA20 | 1.110x | Above |
| vs SMA50 | 1.176x | Above |
| vs SMA200 | 1.529x | Above |

### Decision

- **Verdict:** SELL
- **Thesis:** PARABOLIC

### Trade Setup

- **Entry:** $14.59
- **Stop Loss:** $12.69 (13.0% risk)
- **Target:** $16.49 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** PARABOLIC thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 631
- **Position Value:** $9,206.29
- **Portfolio %:** 9.21%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite as VIX falls to 6th percentile and tech rally resumes on AI infrastructure demand. Fed pause expectations from cooling CPI data support equities, though elevated put/call ratio suggests cautious positioning. Focus on quality names in AI-exposed sectors.*

### Earnings

**Next:** 2026-03-12 (Est: $-0.80)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-1.30 | $-1.20 | +7.6% |
| 2025Q2 | $-1.05 | $-1.38 | -30.8% |
| 2025Q1 | $0.49 | $0.12 | -75.3% |
| 2024Q4 | $-1.08 | $-1.01 | +6.9% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*